Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006. (February 2017) - Long, G.V.; Robert, C.; Arance, A.; Blank, C.; Ribas, A.; Lorigan, P.; Mortier, L.; Schachter, J.; Middleton, M.R.; Neyns, B.; Sznol, M.; Zhou, H.; et al.